Grube Eberhard, Silber Sigmund, Hauptmann Karl Eugen, Buellesfeld Lutz, Mueller Ralf, Lim Victor, Gerckens Ulrich, Russell Mary E
Heart Center Siegburg, Siegburg, Germany.
Am J Cardiol. 2005 Jul 1;96(1):79-82. doi: 10.1016/j.amjcard.2005.03.030.
Early results with polymer-based paclitaxel-eluting stents have shown significant improvements in the clinical and angiographic parameters of restenosis, as well as excellent safety outcomes. However, the duration of these beneficial effects is unknown. Therefore, the clinical outcomes of the TAXUS I study population were evaluated at 2- and 3-year follow-up. In TAXUS I, 61 patients with single, focal coronary lesions were randomly assigned to receive either a paclitaxel-eluting TAXUS stent (n = 31) or a bare metal control stent (n = 30). Low rates of composite major adverse cardiac events (MACEs) reported at 1-year follow-up (3.2% TAXUS vs 10.0% control) were maintained at 2 and 3 years, with no additional MACEs in either treatment group 1 year after implantation. The single target vessel revascularization in the TAXUS group was remote from the target lesion in contrast to 3 target lesion revascularizations in the control group.
基于聚合物的紫杉醇洗脱支架的早期结果显示，在再狭窄的临床和血管造影参数方面有显著改善，并且安全性良好。然而，这些有益效果的持续时间尚不清楚。因此，对TAXUS I研究人群在2年和3年随访时的临床结果进行了评估。在TAXUS I研究中，61名单发局灶性冠状动脉病变患者被随机分配接受紫杉醇洗脱TAXUS支架（n = 31）或裸金属对照支架（n = 30）。1年随访时报道的复合主要不良心脏事件（MACE）发生率较低（TAXUS组为3.2%，对照组为10.0%），在2年和3年时仍维持该水平，植入后1年两个治疗组均未出现额外的MACE。与对照组3例靶病变血运重建相比，TAXUS组的单靶血管血运重建远离靶病变。
